Last year was rather rough for Xoma Corp. In March 2011, the company saw its interleukin-1 beta inhibitor gevokizumab miss its primary endpoint in a Phase IIb trial in Type II diabetes, eliminating the opportunity to enter the lucrative market. (See BioWorld Today, March 24, 2011.)